Compare Five9 Inc (FIVN) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Kymera Therapeutics Inc. Common Stock — how do they compare? Five9 Inc trades at $33.37 (market cap $2.47B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 3.6× Five9 Inc's market cap, and Five9 Inc is more actively traded (1,632,106 versus 1,028,790). Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| FIVN | KYMR | |
|---|---|---|
Market Cap | $2.47B | $8.88B |
Volume | 1,632,106 | 1,028,790 |
Sector | Technology | Health |
52-Week High | $38.65 | $127.31 |
52-Week Low | $13.61 | $55.80 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $2.62B | $8.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $35.41, down 0.73% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates accelerating revenue growth, reaching $1.15B in 2025 with improving profitability as net income turned positive at $39.42M. Recent AI revenue surged 78% to $39M, now representing 15% of subscription revenue, driving investor optimism.
The outlook remains positive with analyst consensus at Buy (61%) and $34 price target, though current price exceeds consensus. Key risks include competitive CCaaS market pressure and insider selling activity. Revenue growth momentum and AI adoption provide upside potential, but valuation multiples remain elevated with P/E of 52 requiring sustained execution.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
